Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesVascular/Cardiothoracic Surgeryblue cross blue shield - louisiana carotid stentin…
    Ask Trek AI about this page
    Modifiedblue cross blue shield - louisianaPolicy 00155

    Extracranial Carotid Angioplasty/Stenting

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy 00155 alerts

    Get alerted when Policy 00155 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage criteria, limitations, and supporting rationale for carotid artery angioplasty with stenting and transcarotid artery revascularization for extracranial carotid stenosis for members of Blue Cross and Blue Shield of Louisiana.

    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyExtracranial Carotid Angioplasty/Stenting
    Policy CodePolicy 00155
    Change TypeCriteria language addedcoding updates
    Effective DateOct 1, 2026
    Last ReviewJul 1, 2027
    Next Review DateJul 20, 2027
    Key ActionObtain prior authorization documenting stenosis severity, symptom timing/status, and any anatomic contraindication or high surgical risk per coverage criteria.
    SourceLink
    POLICY UPDATE CHANGES

    Added 'spinal immobility, or tracheostomy' to the first coverage criteria bullet as examples of anatomic contraindications to carotid endarterectomy.

    Removed ICD-9 diagnosis and procedure code sections and added ICD-10 diagnosis code section; codes 37238 and 37239 were removed from the policy.

    50-99%Severe symptomatic threshold
    70-99%Severe asymptomatic threshold
    180 daysSymptom lookback

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    mRS < 3mRS requirement
    37238/37239Removed CPT codes

    Coverage Criteria for Extracranial Carotid Angioplasty/Stenting

    Symptomatic high-surgical-risk coverage

    Covered when ALL of the following are met

    Symptomatic CAS coverage: Request is for carotid artery angioplasty with placement of an FDA-approved carotid stent and an FDA-approved or cleared embolic protection device
    Stenosis severity: Documented severe carotid artery stenosis with 50-99% stenosis50-99%
    Symptoms timing and type: Symptoms of focal cerebral ischemia ipsilateral to the carotid stenosis: transient ischemic attack or monocular blindness in the previous 180 days with symptom duration <24 hours OR nondisabling stroke in the previous 180 days (modified Rankin scale score <3 at least 30 days after onset)180 days, mRS <3
    High surgical risk: Individual is high risk for carotid endarterectomy due to documented history of ANY of the listed comorbidities or anatomic risk factors (examples: prior radiotherapy or neck surgery; lesion surgically inaccessible; high bifurcation requiring mandibular dislocation; spinal immobility; tracheostomy; age >80; CHF NYHA III/IV or LVEF <30%; open heart surgery needed within 6 weeks; recent MI within 4 weeks; unstable angina CCS III/IV; severe COPD; contralateral carotid occlusion; contralateral laryngeal nerve palsy; significant tandem lesion; restenosis after CEA; stenosis secondary to fibromuscular dysplasia or Takayasu arteritis; carotid pseudoaneurysm)

    Any one listed factor suffices

    Asymptomatic coverage

    Covered when ALL of the following are met

    Procedure and devices: Request is for carotid angioplasty with placement of an FDA-approved carotid stent with an FDA-approved or cleared embolic protection device
    Stenosis severity: Documented severe carotid artery stenosis with 70-99% stenosis70-99%
    Asymptomatic status: Carotid stenosis is asymptomatic with no history of ipsilateral stroke, TIA, or amaurosis fugax within 180 days AND no prior history of disabling stroke (modified Rankin scale score >=3 at least 30 days after onset)180 days, mRS <3
    Medical therapy or contraindication: Documented intensive medical therapy (including aggressive BP management with target systolic <130 mmHg, LDL <70 mg/dL, diabetes management, smoking cessation as applicable) OR documented contraindication(s) to optimal medical therapy

    Coverage criteria and evidentiary conclusions

    Coverage stance summarized from evidence and supplemental information

    CAS for average-risk patients suitable for CEA: Not supported: randomized trial evidence shows higher early adverse events with CAS and similar long-term outcomes compared with CEA; risk of death or stroke with CAS exceeds acceptable thresholds, so CAS does not improve net health outcome for average-risk patients who are candidates for CEA
    CAS medically necessary subgroup: CAS may be considered medically necessary for recently symptomatic patients when CEA cannot be performed due to anatomic reasonsrecently symptomatic

    Based on limited data and clinical input

    TCAR evidence stance: Evidence for TCAR is limited to nonrandomized and observational studies; systematic reviews show no statistically significant difference versus CEA for composite stroke/death/MI but mixed safety signals including elevated risk of death in some analyses

    Role of TCAR remains inadequately established by RCTs

    Coverage conditions and program requirements

    Covered when ALL of the following are met (CMS-based and institutional requirements):

    Primary indication thresholds: Patient meets CMS thresholds: symptomatic stenosis >=50% OR asymptomatic stenosis >=70%symptomatic >=50% OR asymptomatic >=70%

    From CMS national coverage summary

    Pre- and post-procedure neurologic assessment: Neurological assessment by a neurologist or an NIHSS-certified health professional must be performed before and after CASN/A

    Documented neurologic assessment required

    Imaging confirmation: First-line evaluation must use duplex ultrasound; confirm degree of stenosis with CTA or MRA if not contraindicated; use intra-arterial digital subtraction angiography only when noninvasive imaging is discordant or contraindicatedN/A

    Historical coverage context

    Historical coverage context noted by committee approvals

    Context for coverage: Policy history entries record that carotid angioplasty/stenting was considered for symptomatic severe stenosis (>50%) or asymptomatic preocclusive disease (>80%) in patients with anatomic contraindication to carotid endarterectomy (e.g., prior neck surgery, surgically inaccessible lesions)

    Extracted from policy history narrative; not a full criteria set

    Coverage when anatomical contraindication present

    Covered when specified stenosis thresholds are met and anatomic contraindication to carotid endarterectomy is present

    Primary coverage criteria: Patient has symptomatic severe stenosis (>50%) OR asymptomatic preocclusive disease (>80%) AND patient has an anatomic contraindication to carotid endarterectomy (examples: prior radiotherapy or neck surgery; lesions surgically inaccessible; spinal immobility; tracheostomy)symptomatic >50% OR asymptomatic >80%

    Examples of anatomic contraindications were expanded in policy history

    Coverage when stenosis thresholds AND contraindication/high surgical risk present

    Coverage referenced when specific stenosis thresholds and contraindications to endarterectomy are present

    Primary coverage criteria: Patient has symptomatic severe stenosis (>50%) OR asymptomatic preocclusive disease (>80%) AND patient has an anatomic contraindication to carotid endarterectomy (e.g., prior neck radiotherapy or surgery; lesions surgically inaccessible; spinal immobility; tracheostomy) OR patient is high surgical risk due to significant medical diseasesee stenosis thresholds

    Derived from multiple committee approval notes in policy history

    Coverage criteria referenced in policy history

    Policy history describes coverage for extracranial carotid angioplasty/stenting under specific anatomic and clinical conditions

    Symptomatic severe stenosis: Covered for symptomatic severe stenosis (>50%) when anatomic contraindication to carotid endarterectomy exists (examples: prior radiotherapy or neck surgery; lesions surgically inaccessible; immobility; tracheostomy)>50%

    Added to first coverage criteria bullet per history

    Asymptomatic preocclusive disease: Covered for asymptomatic preocclusive disease (>80%) in select contexts; policy history notes removal of a second coverage criterion for asymptomatic >80% and changes related to radiation-induced stenosis>80%

    Second coverage criterion for asymptomatic >80% was removed per history

    High surgical risk: For symptomatic >50% or asymptomatic >80% in patients with significant medical disease making them high risk for surgery, wording was revised (e.g., removal of 'lesions distal or proximal to the usual location')

    Indications for carotid angioplasty and stenting

    Covered when criteria referenced in policy history are met (as described):

    Primary indications: Patient has symptomatic severe carotid stenosis (>50%) OR asymptomatic preocclusive carotid disease (>80%)symptomatic >50%; asymptomatic >80%

    Referenced throughout policy history

    When stenting appropriate instead of CEA: Patient has an anatomic contraindication to carotid endarterectomy (examples: prior neck radiotherapy or surgery; lesions surgically inaccessible; spinal immobility; tracheostomy) OR patient has significant medical disease making them high surgical risk for endarterectomy

    Added/clarified in multiple policy history entries

    Coverage when endarterectomy contraindicated or high surgical risk

    Policy history indicates procedures are considered under specified anatomic and clinical circumstances

    Primary coverage context: Carotid angioplasty and stenting were referenced for patients with symptomatic severe stenosis (>50%) OR asymptomatic preocclusive disease (>80%) when carotid endarterectomy is contraindicated or the patient is high surgical risk due to significant medical diseasesymptomatic >50% OR asymptomatic >80%

    Anatomic contraindications include prior radiotherapy or neck surgery; surgically inaccessible lesions; spinal immobility; tracheostomy

    Coverage when endarterectomy contraindicated or patient high surgical risk

    Coverage considerations described in policy history

    Primary coverage scenario: For symptomatic severe stenosis (>50%) OR asymptomatic preocclusive disease (>80%) in patients with anatomic contraindication to carotid endarterectomy (examples: prior radiotherapy or neck surgery; lesions surgically inaccessible; neck or spinal immobility; tracheostomy)

    Wording was added to the first coverage criteria bullet per multiple policy history entries

    Investigational / not covered when endarterectomy is suitable

    Investigational indications

    Investigational group: Patients with carotid stenosis who are suitable candidates for carotid endarterectomy were added to investigational indications (stenting when endarterectomy is suitable is investigational)

    Stated in policy history

    Coverage criteria and limitations (policy history)

    Policy history indicates covered scenarios and investigational additions/changes

    Stenosis severity: Symptomatic severe stenosis (>50%) OR asymptomatic preocclusive disease (>80%) are the thresholds cited repeatedlysymptomatic >50%; asymptomatic >80%

    Present throughout policy history

    Anatomic contraindication or high surgical risk: Carotid angioplasty/stenting indicated for patients with anatomic contraindication to carotid endarterectomy (examples: prior radiotherapy or neck surgery; lesions surgically inaccessible or immobile; spinal immobility; tracheostomy) OR patients with significant medical disease making them high surgical risk

    Added to first coverage criteria bullet per history

    Investigational addition: Patients who are suitable candidates for carotid endarterectomy were added to investigational indications (i.e., stenting when endarterectomy is suitable is investigational)

    Stated in policy history

    Coverage-related historical criteria

    Historical and criteria notes in the provided chunks reference coverage conditions for carotid angioplasty/stenting

    Coverage-related conditions referenced: Policy history repeatedly references coverage for symptomatic severe stenosis (>50%) and asymptomatic preocclusive disease (>80%) in patients with anatomic contraindications to carotid endarterectomy (examples: prior neck radiotherapy; prior neck surgery; lesions surgically inaccessible; immobility; tracheostomy) or with significant medical disease making them high surgical risk for surgery

    Also notes that patients suitable candidates for carotid endarterectomy were added to investigational indications

    Referenced covered indications

    Coverage language referenced in policy history applies to the following groups

    Covered indications referenced in history: Carotid angioplasty and stent placement considered in patients with symptomatic severe stenosis (>50%) or asymptomatic preocclusive disease (>80%) when there is an anatomic contraindication to carotid endarterectomy (examples: prior neck radiotherapy; prior neck surgery; lesions surgically inaccessible; spinal immobility; tracheostomy)symptomatic >50%; asymptomatic >80%

    Summary of coverage-related wording changes recorded in policy history; full criteria text not present in these chunks

    Coverage when endarterectomy contraindicated or patient high surgical risk

    Covered when ALL of the following are met (as reflected in policy history notes):

    Stenosis severity: Patient has symptomatic severe stenosis (>50%) OR asymptomatic preocclusive disease (>80%)>50% symptomatic; >80% asymptomatic

    Explicitly referenced multiple times in policy history

    Surgical contraindication/high risk: Patient has an anatomic contraindication to carotid endarterectomy (examples: prior radiotherapy or neck surgery; lesions surgically inaccessible; spinal immobility; tracheostomy) OR significant medical disease making the patient high surgical risk

    Added to first coverage bullet per history

    The policy lists specific situations considered not medically necessary. Among these, complete occlusion (100% stenosis) and carotid angioplasty without associated stenting and embolic protection (except rare cases where stenting was intended but prevented by anatomy) are explicitly included as NMN scenarios. These items should be confirmed against clinical documentation when evaluating claims or prior authorization requests.

    The policy states that carotid artery stenting (CAS) is considered investigational for all indications except recently symptomatic patients when carotid endarterectomy (CEA) cannot be performed for anatomic reasons. For recently symptomatic patients who cannot undergo CEA due to anatomic contraindications, CAS may be considered medically necessary; otherwise CAS is not supported for average‑risk patients because randomized trials show higher early adverse events with CAS and similar long‑term outcomes versus CEA.

    The American Stroke Association guidance cited in the policy indicates that carotid revascularization is not recommended for patients with severe disability from cerebral infarction that precludes preservation of useful function. This ASA statement informs exclusion of revascularization in patients with prohibitive baseline functional status.

    The policy references the USPSTF recommendation that screening for asymptomatic carotid artery stenosis in the general adult population is not recommended (Grade D). This recommendation supports limiting screening-driven interventions and aligns with the policy’s emphasis on documented symptomatic status, high‑grade stenosis, or specific contraindications before considering revascularization.

    Coding and Code Updates

    FDA-approved devices (examples)mixed
    PMA and 510(k) device listingsMultiple FDA PMA and 510(k) identifiers listed for carotid stents and embolic protection devices (examples: P030047, P040012, P050019, P060001, P070012, P140026, P180010, P240009, K042218, K062531, K083300, K143072, K153485, K230402, etc.)
    Medicare coverage contextmixed
    not specifiedCMS national coverage summary references CAS/PTA with FDA-approved carotid stent and embolic protection device; exact CPT/HCPCS codes not listed in this excerpt
    Coding updates / Removed CodesCPT
    37238code referenced for removal from policy
    37239code referenced for removal from policy
    Diagnosis codingICD-10
    ICD-10Diagnosis code section added to policy
    Previously listed CPT codes removedCPT
    37238CPT code (referenced for removal from policy)
    37239CPT code (referenced for removal from policy)
    Removed procedure codesCPTNot Covered
    37238procedure code removed from this policy
    37239procedure code removed from this policy
    Diagnosis code system updatesICD-10
    ICD-10ICD-10 diagnosis code section was added to the policy
    Removed procedure codesCPTNot Covered
    37238code noted to be removed from this policy
    37239code noted to be removed from this policy
    Diagnosis code systemICD-10
    ICD-10Diagnosis code section added (ICD-10); ICD-9 removed
    Historical CPT codes removed/updatedCPT
    37238procedure code referenced for removal in policy history
    37239procedure code referenced for removal in policy history
    Coding system changesmixed
    ICD-9ICD-9 procedure/diagnosis code set removed per coding updates
    ICD-10ICD-10 diagnosis code section added per coding updates
    Procedure codes removed from policyCPT
    37238procedure code referenced for removal from policy
    37239procedure code referenced for removal from policy
    Diagnosis code sections updatedmixed
    ICD-10ICD-10 diagnosis code section added
    ICD-9ICD-9 diagnosis and procedure code sections removed
    Removed CPT codesCPT
    37238CPT code referenced for removal from policy
    37239CPT code referenced for removal from policy
    Coding system changesmixed
    ICD-9ICD-9 procedure/diagnosis codes removed from policy
    ICD-10ICD-10 diagnosis code section added to policy
    Historically removed CPT codesCPT
    37238CPT code noted as removed from policy
    37239CPT code noted as removed from policy
    Coding updates (removed)CPT
    37238CPT code noted for removal from this policy
    37239CPT code noted for removal from this policy
    Removed CPT CodesCPT
    37238CPT code referenced for removal from this policy
    37239CPT code referenced for removal from this policy
    Removed ICD-9 Diagnosis CodesICD-10
    ICD-9 (unspecified)ICD-9 diagnosis codes removed per 01/01/2017 coding update
    Coding updates referencedCPT
    37238Code referenced in history as being removed from policy (arterial stent placement codes)
    37239Code referenced in history as being removed from policy (arterial stent placement codes)
    Diagnosis code system changesICD-9
    ICD-9Removal of ICD-9 diagnosis codes (general reference; specific codes not listed in these chunks)
    Coding updates notedmixed
    No codes listed
    inv-70: Asymptomatic stenosis severity — >= 70% stenosis
    Asymptomatic stenosis threshold>= 70% stenosis (documented severe carotid artery stenosis with 70-99% stenosis)
    Required symptom historyNo ipsilateral stroke, TIA, or amaurosis fugax within 180 days
    Medical therapy/documentation

    Prior Authorization, Documentation, and Billing Actions

    Prior Authorization

    Prior authorization required to confirm coverage criteria

    Prior authorization is required to confirm the procedure meets all coverage criteria, including that the request is for carotid artery angioplasty with placement of an FDA‑approved carotid stent and an FDA‑approved or cleared embolic protection device, documented stenosis severity, symptom timing/status, and demonstration of high surgical risk or, for asymptomatic disease, intensive medical therapy/shared decision‑making as applicable.

    • Request must be for CAS with an FDA‑approved carotid stent and FDA‑approved/cleared embolic protection device ([[chunk 3]]).
    • Documentation must show stenosis severity and symptom timing/status per coverage thresholds (symptomatic 50–99% or asymptomatic 70–99%) ([[chunk 3]], [[chunk 5]]).
    • Asymptomatic coverage requires documented intensive medical therapy or contraindication and shared decision‑making ([[chunk 5]]).
    Prior Authorization

    Prior authorization for CAS asserted when CEA not possible (recently symptomatic)

    When CAS is asserted as medically necessary because CEA cannot be performed for anatomic reasons in recently symptomatic patients, prior authorization is implied but the request must include documentation that the patient is recently symptomatic and not a candidate for CEA due to anatomic contraindication.

    Background and Rationale

    Carotid artery stenting (CAS) and transcarotid artery revascularization (TCAR) are described as less‑invasive alternatives to carotid endarterectomy (CEA). CAS is typically performed via transfemoral or transcervical approaches using embolic protection devices, while TCAR employs a direct cervical approach with dynamic flow reversal. Evidence for CAS includes randomized controlled trials comparing CAS and CEA; evidence for TCAR is limited to nonrandomized and observational studies and systematic reviews. These distinctions support the policy’s more restrictive coverage stance for CAS/TCAR compared with CEA.

    Coverage decisions in this policy are informed by guideline documents and systematic reviews cited in the references (for example, ROADSTER trial publications and the 2011 ASA/ACC/AHA guideline). While the excerpted references inform clinical context and recommendations, the policy text applies specific coverage criteria and investigational designations rather than listing every guideline‑based exclusion explicitly.

    The policy history documents multiple revisions over time but the provided excerpt does not present a separate, comprehensive list labeled 'not medically necessary.' Instead, the NMN examples are embedded within the 'When Services Are Considered Not Medically Necessary' and policy‑history text; explicit NMN wording beyond those embedded examples is not shown in this excerpt.

    Definitions and Thresholds

    inv-147: Modified Rankin Scale (mRS) — defines non-disabling stroke (mRS < 3)
    mRS purposeModified Rankin Scale (mRS) measures functional independence after stroke on a seven-grade scale
    Non-disabling stroke definitionNon-disabling stroke defined as mRS < 3 at least 30 days after onset
    Use in policymRS used to determine eligibility for revascularization (excludes patients with disabling stroke)
    inv-148: Severe carotid stenosis — guideline definition (≥70% noninvasive or >50% angiography)
    Guideline severe carotid stenosisTypically defined as ≥70% by noninvasive imaging or >50% by catheter angiography for symptomatic patients
    Periprocedural risk considerationGuidelines recommend CEA for 70–99% symptomatic stenosis when perioperative morbidity/mortality estimated <6%

    Policy Revision History and Material Changes

    05/05/2016Medical Policy Committee review

    Medical Policy Committee reviewed and revised coverage language; coding updates and criteria wording edits (including plans to remove CPT codes 37238/37239) were recorded.

    05/18/2016Implementation Committee review

    Implementation activities following Medical Policy Committee decisions; coding and policy language changes documented.

    07/19/2017Medical Policy Implementation Committee approval
    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyExtracranial Carotid Angioplasty/Stenting
    Policy CodePolicy 00155
    Change TypeCriteria language addedcoding updates
    Effective DateOct 1, 2026
    Last ReviewJul 1, 2027
    Next Review DateJul 20, 2027
    Key ActionObtain prior authorization documenting stenosis severity, symptom timing/status, and any anatomic contraindication or high surgical risk per coverage criteria.
    SourceLink
    On This Page
    Coverage Criteria for Extracranial Carotid Angioplasty/StentingCoding and Code UpdatesPrior Authorization, Documentation, and Billing ActionsBackground and RationaleDefinitions and ThresholdsPolicy Revision History and Material Changes
    BP <130, LDL <70
    Shared decision-making is documented and the individual is informed of revascularization risks including stroke and death
    Revascularization vs medical therapy (asymptomatic): CREST-2 found CAS plus intensive medical management reduced the primary composite outcome versus medical management alone in the CAS trial, but CEA plus medical management did not show a significant difference versus medical management alone; guideline/editorial guidance suggests initiating intensive medical therapy and deferring routine revascularization for many asymptomatic patientshigh-grade >=70%

    Consider revascularization selectively

    Imaging sequence requirement

    Shared decision-making: A formal shared decision-making interaction covering all treatment options (CEA, CAS/TCAR, OMT), individualized risks/benefits, guideline integration, and patient preferences must be conducted prior to CASN/A

    Required prior to furnishing CAS

    Facility program standards: Facility must maintain a dedicated carotid stent program with defined privileging, outcome monitoring, oversight committee setting minimum case volumes and complication thresholds, appropriately trained staff, and necessary imaging/monitoring/support services with continuous quality improvementN/A

    Institutional requirements for program operation

    Policy history documents revision for high surgical risk wording

    Documented intensive medical therapy (BP <130 mmHg; LDL <70 mg/dL) or contraindication to optimal medical therapy
    inv-71: Symptomatic stenosis severity — 50-99% stenosis
    Symptomatic stenosis threshold50-99% stenosis (documented severe carotid artery stenosis)
    Symptom timing windowIpsilateral TIA/monocular blindness or nondisabling stroke within previous 180 days
    Disability requirementNondisabling stroke defined as modified Rankin Scale score <3 at least 30 days after onset
    inv-72: Stenosis thresholds — guideline definitions for severe stenosis
    Guideline severe-stenosis definition (noninvasive)>=70% by noninvasive imaging for symptomatic patients (per ASA/AHA guidance)
    Guideline severe-stenosis definition (angiography)>50% by catheter-based angiography for symptomatic patients
    Asymptomatic prophylactic threshold noteProphylactic consideration: minimum 60% by angiography or 70% by validated Doppler for selected asymptomatic patients
    inv-73: Stenosis threshold for coverage — Symptomatic >=50%; Asymptomatic >=70%
    CMS-based coverage thresholdsSymptomatic >=50% OR Asymptomatic >=70% (CMS national coverage)
    Program requirementsPre/post neurologic assessment and confirmatory imaging per CMS (duplex first-line; CTA/MRA or catheter angiography if indicated)
    Shared decision-makingFormal shared decision-making covering CEA, CAS/TCAR, and optimal medical therapy required prior to CAS
    inv-74: Stenosis severity thresholds (historical) — >50% symptomatic; >80% asymptomatic
    Historical symptomatic threshold>50% symptomatic (historical policy language referencing symptomatic severe stenosis >50%)
    Historical asymptomatic threshold>80% asymptomatic (asymptomatic preocclusive disease referenced historically)
    ContextThese thresholds are cited repeatedly in policy history entries documenting past coverage criteria
    • Policy notes CAS may be considered medically necessary for recently symptomatic patients when CEA cannot be performed for anatomic reasons; include documentation of inability to perform CEA ([[chunk 21]]).
    • Coverage criteria for symptomatic patients (including timing and stenosis thresholds) still apply ([[chunk 3]]).
    Prior Authorization

    Prior authorization must document indication and program compliance

    Prior authorization submissions must demonstrate the patient meets CMS‑consistent coverage conditions (symptomatic stenosis ≥50% or asymptomatic ≥70%) and that required pre/post procedure assessments and facility program standards are met.

    • CMS criteria: symptomatic ≥50% or asymptomatic ≥70% ([[chunk 38]]).
    • Pre/post neurologic assessment, imaging confirmation, formal shared decision‑making, and facility program standards are required and should be documented ([[chunk 39]], [[chunk 40]]).
    Note

    Prior authorization (check full policy for PA process)

    Policy history documents multiple coverage eligibility revisions and coding changes, but the excerpt does not restate an explicit step‑by‑step prior authorization process; providers should consult the full policy and payer authorization portal for procedural PA instructions.

    • Policy history shows many committee reviews and coding updates but does not specify the explicit PA workflow in these excerpts ([[chunk 58]], [[chunk 90]]).
    Billing Rule

    Coding/coverage history: CPT codes 37238 and 37239 removed

    Policy history repeatedly documents removal of CPT codes 37238 and 37239; these CPT removals are noted in multiple coding updates and may affect which codes are accepted for authorization.

    • Coding update entries state codes 37238 and 37239 will be removed from the policy (multiple policy history entries) ([[chunk 72]], [[chunk 126]]).
    Note

    Coding update may affect authorization (37238/37239 removed)

    Coding updates removing CPT codes 37238 and 37239 are recorded in the policy history and may affect prior authorization routing and code validation during submission.

    • Coding update entries note removal of 37238 and 37239 and multiple implementation committee reviews (03/24/2016 and related entries) ([[chunk 90]], [[chunk 160]]).
    Prior Authorization

    Use current procedure codes and document indications for PA/billing

    Ensure prior authorization and billing use current, supported procedure codes and include documentation of the clinical indications (e.g., symptomatic >50% or asymptomatic >80% with contraindication/high surgical risk) rather than the removed CPTs.

    • Policy history instructs use of current codes and supporting clinical criteria; removed codes 37238/37239 should not be used for claims or PA ([[chunk 110]]).
    • Include clinical documentation of stenosis severity and relevant contraindications/high surgical risk per coverage criteria ([[chunk 3]]).
    Billing Rule

    Coding update affecting billed CPTs (37238/37239 removal noted)

    Policy history entries document planned removal of CPT codes 37238 and 37239; providers should confirm which CPTs to bill and which the payer accepts when seeking authorization.

    • Multiple history notes state codes 37238 and 37239 will be removed from the policy (03/24/2016 and later entries) ([[chunk 126]], [[chunk 98]]).
    Billing Rule

    Coding update affecting billed CPTs — removal reiterated

    The policy history repeatedly records removal of CPT codes 37238 and 37239; prior authorization requests should reference currently supported procedure codes rather than the removed codes.

    • Entries across policy history reiterate removal of 37238 and 37239 and implementation committee approvals—do not rely on removed codes for PA ([[chunk 160]], [[chunk 209]]).
    Prior Authorization

    Prior authorization and coding note — reference valid codes

    When submitting prior authorization, reference valid, current procedure codes (not removed codes 37238/37239) and include the clinical documentation required by coverage criteria.

    • Policy history advises that removal of 37238/37239 requires PA to reference current valid coding and diagnostic criteria (symptomatic >50% or asymptomatic >80%) ([[chunk 93]]).
    • Include documentation of stenosis severity and relevant contraindications per coverage criteria ([[chunk 3]]).
    Billing Rule

    Coding update — affected CPT codes referenced

    Coding updates in the policy history list CPT codes 37238 and 37239 among affected procedure codes; providers should verify current CPT guidance before billing or PA submission.

    • Policy history repeatedly references 37238 and 37239 being removed from the policy (implementation and coding update entries) ([[chunk 164]], [[chunk 126]]).
    Prior Authorization

    Use current CPT codes and document criteria for PA

    The policy removes CPT codes 37238 and 37239 in multiple history entries; prior authorization and billing must use currently supported CPTs and clearly document how the case meets criteria (stenosis thresholds and contraindication/high surgical risk).

    • Coding updates removed 37238/37239; PA should use current CPTs and reflect coverage criteria (symptomatic >50% or asymptomatic >80% with listed contraindications/high surgical risk) ([[chunk 180]], [[chunk 3]]).
    Note

    Coding update / prior authorization note (removed CPTs)

    Coding updates note removal of CPT codes 37238 and 37239 from the policy; the provided excerpt does not restate explicit prior authorization requirements tied to this change.

    • Policy history documents CPT removals but does not detail a changed PA workflow in these chunks ([[chunk 209]], [[chunk 98]]).
    Note

    Coding update / CPT removals noted (PA not restated in excerpt)

    Policy history records removal of CPT codes 37238 and 37239; those coding changes are documented but the excerpt does not explicitly restate PA triggers tied to these removals.

    • Multiple history notes reference removal of 37238/37239; PA implications are implied but not explicitly described in these excerpts ([[chunk 216]], [[chunk 234]]).
    Prior Authorization

    Prior authorization implications from coverage revisions

    Policy history revisions to coverage criteria—such as expanding examples of anatomic contraindications—could change prior authorization determinations; include documentation of any cited anatomic contraindication in PA submissions.

    • History entries added 'spinal immobility, or tracheostomy' to examples of anatomic contraindications in the first coverage bullet ([[chunk 96]]).
    • Policy history emphasizes documenting anatomic contraindications when claiming stenting instead of CEA ([[chunk 252]]).
    Prior Authorization

    PA: demonstrate stenosis severity and anatomic contraindications

    Prior authorization requests should include documentation showing the degree of stenosis and the specific anatomic contraindication or high surgical risk that makes CEA infeasible.

    • Policy history and coverage criteria require documented stenosis severity and demonstration of anatomic contraindication or high surgical risk ([[chunk 252]], [[chunk 3]]).
    Step Therapy

    Medical therapy requirement before authorization for asymptomatic disease

    For asymptomatic high‑grade stenosis, prior authorization and documentation should show the patient received intensive medical therapy (targets: systolic BP <130 mmHg, LDL <70 mg/dL) or has a contraindication to optimal medical therapy before coverage of revascularization is considered.

    • Asymptomatic coverage requires documented intensive medical therapy with BP target <130 mmHg and LDL <70 mg/dL or documented contraindication to optimal medical therapy ([[chunk 5]]).
    Step Therapy

    Document prior medical management before revascularization

    Conservative management with intensive medical therapy is the recommended initial approach for many patients with asymptomatic high‑grade stenosis; prior authorization should reflect that revascularization was considered after optimal medical therapy or appropriate exceptions.

    • CREST‑2 and editorial guidance recommend initiating intensive medical therapy and delaying revascularization for asymptomatic patients; PA should document this rationale when applicable ([[chunk 19]]).
    • Asymptomatic coverage criteria require either intensive medical therapy or documented contraindication ([[chunk 5]]).
    Documentation Required

    Document shared decision‑making prior to authorization

    Prior authorization submissions must document that a shared decision‑making discussion occurred covering CEA, CAS/TCAR, and optimal medical therapy and that patient preferences were considered.

    • CMS‑aligned requirements and policy text require a formal shared decision‑making interaction discussing CEA, CAS/TCAR, and OMT prior to CAS ([[chunk 39]]).
    • Asymptomatic coverage criteria explicitly require documentation of shared decision‑making ([[chunk 5]]).
    Documentation Required

    Required documentation: stenosis percent and symptom timing

    Document the percent stenosis, symptomatic history with timing (including ipsilateral TIA, monocular blindness, or nondisabling stroke), and modified Rankin Scale status when submitting for prior authorization.

    • Coverage requires documented severe stenosis percent and symptom timing/type (e.g., ipsilateral TIA or monocular blindness within 180 days or nondisabling stroke with mRS <3) ([[chunk 3]]).
    • Required documentation list emphasizes percent stenosis, symptom history/timing, and mRS score ([[chunk 115]]).
    Documentation Required

    Documentation: symptomatic status and imaging‑confirmed stenosis

    Include the patient's symptomatic status and the degree of stenosis as measured by duplex ultrasound, CTA/MRA, or catheter angiography in the prior authorization package.

    • Documentation should include symptomatic status and degree of stenosis by appropriate imaging modality (≥70% symptomatic severe stenosis or thresholds per policy) ([[chunk 116]]).
    • Policy lists duplex ultrasound as first‑line and CTA/MRA or catheter angiography for confirmation when indicated ([[chunk 39]]).
    Documentation Required

    Neurologic assessment and imaging documentation required

    Prior authorization and documentation must include neurologic assessment by a neurologist or an NIHSS‑certified professional before and after CAS, and duplex ultrasound results as part of the imaging confirmation.

    • Policy requires neurologic assessment by a neurologist or NIHSS‑certified professional before and after CAS ([[chunk 39]]).
    • Duplex ultrasound is specified as first‑line evaluation and must be included in documentation ([[chunk 39]]).
    Billing Rule

    Use ICD‑10 diagnosis coding for PA and claims

    Use appropriate ICD‑10 diagnosis codes when submitting claims or prior authorization requests; the policy added an ICD‑10 diagnosis code section and removed ICD‑9 codes.

    • Policy history documents addition of an ICD‑10 diagnosis code section and removal of ICD‑9 procedure/diagnosis sections—use ICD‑10 for submissions ([[chunk 69]], [[chunk 90]]).
    Documentation Required

    Support anatomic contraindication with documentation

    When asserting anatomic contraindication to CEA, include supporting documentation such as prior neck radiotherapy or surgery, surgically inaccessible lesions, spinal immobility, or tracheostomy.

    • Policy history expanded examples of anatomic contraindications to include prior radiotherapy/neck surgery, surgically inaccessible lesions, spinal immobility, or tracheostomy and advises documenting these conditions ([[chunk 96]], [[chunk 252]]).
    Documentation Required

    Clinical justification: document stenosis severity and contraindication/high risk

    Provide clinical justification for stenting by documenting stenosis severity (symptomatic >50% or asymptomatic preocclusive >80%) and either an anatomic contraindication to CEA or that the patient is high surgical risk due to medical comorbidity.

    • Policy history and coverage criteria require documentation of stenosis thresholds and presence of anatomic contraindication or high surgical risk when claiming stenting ([[chunk 108]], [[chunk 3]]).
    Denial Risk

    Denial triggers: requests not meeting coverage criteria

    Requests that do not meet coverage criteria—such as procedures for patients suitable for CEA, complete occlusion (100% stenosis), angioplasty without stent/embolic protection, lack of required imaging/embolic protection, or lesions not safely reachable endovascularly—may be denied.

    • Policy lists not medically necessary indications including patients suitable for CEA, complete occlusion, angioplasty without stent/EPD, asymptomatic stenosis not meeting criteria, and lesions not safely reachable endovascularly ([[chunk 6]]).
    • Coverage criteria require use of an FDA‑approved stent with embolic protection and imaging‑confirmed stenosis thresholds ([[chunk 3]]).
    Denial Risk

    Denial risk: CAS not supported for average‑risk candidates for CEA

    CAS requests for average‑risk patients who are suitable candidates for CEA may be denied because randomized trial evidence shows higher early adverse events with CAS and no net health benefit compared with CEA for average‑risk patients.

    • Summary of evidence states CAS is not supported for average‑risk patients suitable for CEA due to higher early adverse events and similar long‑term outcomes ([[chunk 18]]).
    • Policy lists individuals suitable for CEA among not medically necessary indications for CAS ([[chunk 6]]).
    Denial Risk

    Coding removal note: removed CPTs may cause denials

    Removal of CPT codes 37238 and 37239 is repeatedly documented; submitting claims or authorization requests using removed codes may result in coding‑related denials or request for corrected coding.

    • Policy history explicitly notes codes 37238 and 37239 will be removed from the policy in multiple entries ([[chunk 73]], [[chunk 126]]).
    • Coding removal is listed as a potential cause for coding‑related denials in the brief.
    Imaging concordanceThresholds apply based on imaging modality used (noninvasive vs angiography)
    inv-149: Recently symptomatic — TIA or nondisabling ischemic stroke within prior 6 months
    Recently symptomatic timeframePatients with TIA or nondisabling ischemic stroke within the prior 6 months (180 days)
    ApplicabilityApplies to consideration of CAS when CEA cannot be performed for anatomic reasons
    Evidence basisLimited data and clinical input support CAS as reasonable for recently symptomatic patients when CEA is not possible
    inv-150: carotid artery angioplasty with stenting (CAS) — short label
    Short labelCAS = carotid artery angioplasty with stenting
    Device requirementCAS requires placement of an FDA-approved carotid stent with an FDA-approved or cleared embolic protection device per policy
    Alternative termIncludes transcarotid approaches (TCAR) as part of CAS discussion
    inv-151: transcarotid artery revascularization (TCAR) — included within CAS discussion
    TCAR inclusionTCAR is included within the CAS discussion and treatment options discussed during shared decision-making
    Approach noteTCAR uses a transcervical/transcarotid approach and is discussed alongside transfemoral CAS and CEA
    Evidence sourcesTCAR is referenced in systematic reviews and ROADSTER trials cited in the policy references
    inv-152: TCAR — referenced in ROADSTER trials and systematic reviews (dynamic flow reversal)
    TCAR evidenceTCAR is referenced in ROADSTER trials and multiple systematic reviews comparing dynamic flow reversal TCAR to transfemoral CAS and CEA
    Study examplesROADSTER and ROADSTER-2 cited; systematic reviews (Ann Vasc Surg, Front Cardiovasc Med) included in references
    LimitationsEvidence mainly nonrandomized/observational; systematic reviews show mixed safety signals
    inv-153: Patient populations referenced — symptomatic >50% or asymptomatic >80%; anatomic contraindication example groups
    Primary patient groups referencedSymptomatic >50% or asymptomatic >80% (historical policy language)
    Anatomic contraindication examplesPatients with prior neck radiotherapy, prior neck surgery, or surgically inaccessible lesions referenced
    High surgical risk noteAlso references patients with significant medical disease that make them high surgical risk
    inv-154: Anatomic contraindication — examples include prior radiotherapy, neck surgery, surgically inaccessible lesions
    Examples of anatomic contraindicationPrior radiotherapy to the neck; prior neck surgery; lesions surgically inaccessible
    Additional examples addedSpinal immobility and tracheostomy added as examples of anatomic contraindication to CEA
    Policy historyThese examples were expanded in policy history entries and added to the first coverage criteria bullet
    inv-155: Symptomatic severe stenosis — >50% stenosis (definition block)
    Symptomatic severe stenosis definition>50% stenosis noted as symptomatic severe stenosis in policy language
    Documentation requirementStenosis percentage must be documented (percent) using appropriate imaging modality
    Eligibility contextUsed in coverage criteria for CAS when patient is high surgical risk or has contraindication to CEA
    inv-156: Asymptomatic preocclusive disease — >80% stenosis
    Asymptomatic preocclusive disease threshold>80% stenosis referenced historically as asymptomatic preocclusive disease
    Policy history noteSecond coverage criterion for asymptomatic >80% was removed in history entries; current asymptomatic coverage uses >=70% in main criteria
    DocumentationDegree of stenosis must be documented using duplex/CTA/MRA or catheter angiography as indicated
    inv-160: Anatomic contraindication to carotid endarterectomy — now includes spinal immobility and tracheostomy in examples
    CAS short labelCarotid artery angioplasty with stenting (CAS)
    TCAR relationTCAR is a transcarotid approach discussed within CAS and studied in ROADSTER trials (dynamic flow reversal)
    Evidence mentionSystematic reviews and ROADSTER trials cited support discussion of TCAR within CAS literature

    Committee approved implementation of prior coding updates and policy revisions, including removal of ICD-9 sections and addition of ICD-10 diagnosis section.

    01/01/2017Coding system update effective date

    ICD-9 diagnosis codes removed from policy and ICD-10 diagnosis code section added effective 01/01/2017.

    05/20/2015Medical Policy Committee approval

    Earlier committee approval recorded in policy history as part of recurring reviews of coverage criteria and coding.

    07/06/2017Policy history coding update

    Policy history entry notes updates to procedure coding and removal of procedure codes (including 37238/37239) from the policy.

    2026-10-01Policy effective dateLatest

    Current policy effective date established as 2026-10-01 with updated coverage criteria and expanded examples of anatomic contraindications.

    Material updates in the policy history include expansion of examples of anatomic contraindications to CEA—specifically adding spinal immobility and tracheostomy to the first coverage criteria bullet—and coding updates removing CPT codes 37238 and 37239 and replacing ICD‑9 sections with ICD‑10 diagnosis coding. These changes affect documentation and coding expectations for prior authorization and claims.